ArticleBiological procedures online2019
MBEC Versus MBIC: the Lack of Differentiation between Biofilm Reducing and Inhibitory Effects as a Current Problem in Biofilm Methodology.
Article in Biological procedures online, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 128 citations in OpenAlex.
- Emerging role of essential oil biomolecules: a sustainable therapeutic approach to combat microbial pathogens.Archives of microbiology · 2026Review
- Data-Driven Engineering of Antimicrobial Nanomaterials for Food Safety and Biomedical Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- Epidemiological Study of the Relationship Between Antimicrobial Resistance Genes and Biofilm-Forming Capacity in Pathogens Causing Chronic Wound Infections.Microorganisms · 2026Article
- Exploring the Activity of Bacteriocins Against Bacterial Biofilms Using a Simple and Inexpensive Assay.Probiotics and antimicrobial proteins · 2026Article
- Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems.The Journal of antimicrobial chemotherapy · 2026Review
- From Membrane Composition to Antimicrobial Strategies: Experimental and Computational Approaches to AMP Design and Selectivity.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Can commensals alter pathogen's antibiotic resistance during co-culture?Journal of medical microbiology · 2026Article
- Food safety culture and the control of microbial communities in food production environments.npj antimicrobials and resistance · 2026Review
- Overcoming Candida albicans biofilm drug resistance via azole-sophorolipid synergy.Scientific reports · 2026Article
- Stress-Induced Plant Specialized Metabolism: Signaling, Multi-Omics Integration, and Plant-Derived Antimicrobial Metabolites to Combat Antimicrobial Resistance.Plants (Basel, Switzerland) · 2026Review
- UnderstandingMicroorganisms · 2026Review
- Molecular mechanisms of antibiotic resistance in Gram-positive and Gram-negative bacteria - a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Inhibitory effect of fluoroquinolones against biofilm formation by Staphylococcus aureus isolated from milk of dairy cows with mastitis.The Journal of veterinary medical science · 2026Article
- Hypertonic thermal solutions as a putative strategy for respiratory biofilm disruption.Open medicine (Warsaw, Poland) · 2026Article
- Comprehensive chemical profiling and bioactivity assessment of Porodaedalea pini and Phellinus tremulae.Scientific reports · 2025Article
- Article
- The Role of Carbenicillin as an Inhibitor of the Biofilm Regulator CsgD in Salmonella Typhimurium.MicrobiologyOpen · 2025Article
- Asiatic Acid Disrupts the Biofilm Virulence ofInternational journal of molecular sciences · 2025Article
- UropathogenicInternational journal of molecular sciences · 2025Article
- A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.Medical microbiology and immunology · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiofilms are communities of aggregated, matrix-embedded microbial cells showing a high tolerance to an in principle adequate antibiotic therapy, often resulting in treatment failure. A major challenge in the management of biofilm-associated infections is the development of adequate, standardized biofilm susceptibility testing assays that are clinically meaningful, i.e. that their results correlate with treatment outcome. Different biofilm susceptibility endpoint parameters like the minimal biofilm eradication concentration (MBEC) or the minimal biofilm inhibitory concentration (MBIC) have been suggested as a guide for treatment of biofilm-associated infections, however with inconsistent perception and use among biofilm researchers, leading to confusion and contradictions among different anti-biofilm component studies and clinical trials.
findingsEvaluation of anti-biofilm effects is mostly based on the untreated reference growth control biofilm measured at the same endpoint as the treated biofilm, neglecting the possible change of the untreated reference biofilm from the time point of pre-antimicrobial exposure to the measured endpoint. In this commentary, we point out the importance of individual quantification of mature, established biofilms before antimicrobial treatment for each biofilm model in order to draw conclusions on the measured biofilm effect size, i.e. biofilm reducing (MBEC) or biofilm inhibitory (MBIC) effects.
conclusionThe assessment of pre-treatment biofilms contributes to a standardized use of biofilm susceptibility endpoint parameters, which is urgently needed to improve the clinical validity of future anti-biofilm assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.